{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009950","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.140219+00:00","generated_at":"2026-06-04T19:48:01.486600+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Co-Diagnostics FY2023 revenue drops 80% to $6.8M; net loss widens to $35.3M","bullets":["Revenue of $6.8M, down from $34.2M in 2022, driven by decline in COVID-19 test demand.","Net loss of $35.3M ($1.20 per diluted share) vs. $14.2M ($0.45) in prior year.","Operating loss of $42.7M; adjusted EBITDA loss of $33.0M.","Submitted EUA to FDA for Co-Dx PCR Pro platform and COVID-19 test in December 2023.","Appointed Ivory Chang as Chief Regulatory Affairs Officer; secured $12.6M in grants for TB, respiratory, HPV tests."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009950","json":"https://secwatch.observer/filing/0001493152-24-009950.json","markdown":"https://secwatch.observer/filing/0001493152-24-009950.md","text":"https://secwatch.observer/filing/0001493152-24-009950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224009950/0001493152-24-009950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224009950/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:48:01.486600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e1c7632a0dfc78fc5fb54c0852581f83dd297ff9","claim":"Co-Diagnostics, Inc. reported the full year ended December 31, 2023 results: revenue $6.8 million, net income Net loss of $35.3 million, EPS a loss of $1.20 per fully diluted share.","evidence_excerpt":"the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023. Full Year 2023 Financial Results: ● Revenue of $6.8 million, down from $34.2 million during the prior year primarily due to the decline in global demand for the Logix Smart® COVID-19 tests. Grant revenue totaled $5.8 million while","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224009950/0001493152-24-009950-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"$6.8 million"},{"label":"Net income","value":"Net loss of $35.3 million"},{"label":"EPS","value":"a loss of $1.20 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}